Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
When Should an Emerging Biotech Bring Commercial Leadership Into the Organization?
The key question is not how many months before launch to hire a CCO—it is when decisions require experienced commercial leadership.
Read articleCommercial Due Diligence for Biotechnology Assets: Look Beyond the Forecast
Effective commercial due diligence focuses on the assumptions connecting clinical performance to commercial adoption—not spreadsheet precision alone.
Read articleWhy Market Access Planning Must Start Before FDA Approval
Approval answers whether a product can be made available. It does not answer whether patients can realistically receive it.
Read articleShould an Emerging Biotech Commercialize Independently or Partner?
Neither strategy is universally correct. The decision should begin with a realistic understanding of what commercialization actually requires.
Read articleA Commercial Readiness Checklist for a Biotech Company's First Product Launch
A first product launch is a company transformation. Leadership should evaluate readiness across market understanding, access, organization, governance and execution.
Read articleWhen Should an Emerging Biotechnology Company Start Commercial Planning?
Commercialization is not an event that begins when a commercial organization is hired. It is the culmination of decisions made throughout development.
Read articleCAH Commercialization
Why commercial success for atumelnant will depend on diagnosis, market strategy, and commercial discipline—not pharmacology alone.
Read articleThe Eight Principles of Product Commercialization
A successful product launch begins long before FDA approval—commercialization is a series of strategic decisions that determine whether an innovative therapy reaches patients.
Read article